Montana’s SB535 and a Potential Biotech Renaissance in America

Short summary

China approved 83 drugs in 2024 versus the FDA's 50, and now dominates global clinical trials at 30% share, up from 8% in 2013. Chinese Jiangsu Hengrui Pharmaceuticals recently surpassed AstraZeneca as the world's top clinical trial sponsor. This shift reflects growing biotech competitiveness from China and raises questions about America's regulatory environment.

• •China approved 83 new drugs in 2024 vs FDA's 50
• •Chinese companies now sponsor 30% of global clinical trials, up from 8% in 2013
• •Jiangsu Hengrui Pharmaceuticals became top global trial sponsor, surpassing AstraZeneca

Generated with AI, which can make mistakes.